Advanced hybrid closed-loop therapy reduces HbA1c and improves time in range among adolescents and young adults with type 1 diabetes, with few serious adverse events, according to findings ...

The trial followed patients with type 1 diabetes (T1D) for 6 months, evaluating outcomes in patients struggling to achieve glucose targets with the conventional treatment.